Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Lexaria Bioscience Corp has a consensus price target of $8 based on the ratings of 2 analysts. The high is $12 issued by Maxim Group on March 5, 2024. The low is $4 issued by HC Wainwright & Co. on July 29, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on July 29, 2025, July 1, 2025, and January 24, 2025, respectively. With an average price target of $5.33 between HC Wainwright & Co., there's an implied 499.18% upside for Lexaria Bioscience Corp from these most-recent analyst ratings.
1calculated from analyst ratings
| Get Alert | |||||
|---|---|---|---|---|---|
| Jul 29, 2025 | 349.39% | 45 | Previous Buy Current Buy | Get Alert | |
| Jul 1, 2025 | 461.73% | 57 | Previous Buy Current Buy | Get Alert | |
| Jan 24, 2025 | 686.43% | 710 | Previous Buy Current Buy | Get Alert | |
| Dec 2, 2024 | 1023.47% | 1010 | Previous Buy Current Buy | Get Alert | |
| Nov 25, 2024 | 1023.47% | 1010 | Previous Buy Current Buy | Get Alert | |
| Jul 18, 2024 | 1023.47% | 1010 | Previous Buy Current Buy | Get Alert | |
| Jul 10, 2024 | 1023.47% | 10 | Previous Initiates Current Buy | Get Alert | |
| Mar 5, 2024 | 1248.16% | 312 | Previous Buy Current Buy | Get Alert | |
| Jul 21, 2023 | 124.69% | 2 | Previous Initiates Current Buy | Get Alert |
The latest price target for Lexaria Bioscience (NASDAQ:LEXX) was reported by HC Wainwright & Co. on July 29, 2025. The analyst firm set a price target for $4.00 expecting LEXX to rise to within 12 months (a possible 349.39% upside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for Lexaria Bioscience (NASDAQ:LEXX) was provided by HC Wainwright & Co., and Lexaria Bioscience maintained their buy rating.
There is no last upgrade for Lexaria Bioscience
There is no last downgrade for Lexaria Bioscience.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lexaria Bioscience, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lexaria Bioscience was filed on July 29, 2025 so you should expect the next rating to be made available sometime around July 29, 2026.
While ratings are subjective and will change, the latest Lexaria Bioscience (LEXX) rating was a maintained with a price target of $5.00 to $4.00. The current price Lexaria Bioscience (LEXX) is trading at is $0.89, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.